Intas Pharmaceuticals concluded the sole licence agreement with Meiji and Socio Dong-A Holdings to market the proposed biosimilitary antibody ustekinumab to treat diseases like plaque psoriasis, Crohn’s disease and ulcerative colitis, according to the company in a declaration. Intas Pharmaceuticals has entered into an exclusive licence agreement.
Under the terms of the agreement, Intas has been granted exclusive license rights to commercialise DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia. Meiji and Dong-A ST will develop and manufacture DMB-3115 and supply the product to Intas and its worldwide affiliates, it added.
“We are excited by this partnership, which brings together the development expertise of Meiji and Dong-A ST with the extensive commercial reach of Intas,” said Binish Chudgar, Vice Chairman.
The statement said that this is another industry first for Intas, one of the leaders in the development and commercialisation of biosimilar products, the first Indian company to launch a biosimilar product in the European Union (EU).
Adding to it, Chrys Kokino, President, Accord BioPharma, the US specialty subsidiary of Intas, said, “This agreement underlines our vision and commitment to increasing access to life-changing medicines that can make a real difference to patient lives across the world.”
